Steminent Biotherapeutics Inc. They are dedicated to developing novel cellular therapeutics for diseases with unmet medical needs. Steminent utilizes advanced proprietary processes to isolate, purify, and amplify standardized stem cell products of the highest quality for research and clinical development in various indications.

Their portfolio includes the Stemchymal® platform, which consists of a range of Stemchymal® cell therapy programs initially targeting neurodegenerative and degenerative diseases. Steminent has built a pipeline of pre-clinical and clinical stage therapeutic programs for the treatment of diseases such as spinocerebellar ataxia, osteoarthritis of the knee, and other neurodegenerative diseases. With strong pre-clinical data, early PI/II clinical data, and a thorough CMC approach, Steminent advances selected Stemchymal® cellular therapeutic programs with the support and direction of scientific, clinical, and regulatory advisors and collaborators worldwide.

Steminent's goal is to translate their technology platform into numerous cellular therapeutic candidates for clinical development and optimize commercialization potential through global partnering initiatives, ultimately building substantial value for shareholders